NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · IEX Real-Time Price · USD
1.820
+0.090 (5.20%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Company Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.
Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis.
The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease.
NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd.
Country | Israel |
Founded | 2017 |
IPO Date | Dec 9, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 14 |
CEO | Alon Ben-Noon |
Contact Details
Address: 11 Hamenofim St., Building B Herzliya, L3 4672562 Israel | |
Phone | 972-9-9531142 |
Website | neurosense-tx.com |
Stock Details
Ticker Symbol | NRSN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $6.00 |
CIK Code | 0001875091 |
CUSIP Number | M74240108 |
ISIN Number | IL0011809592 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Alon Ben-Noon | Co-Founder, Chief Executive Officer and Director |
Or Eisenberg | Chief Financial Officer |
Dr. Ferenc Tracik M.D. | Chief Medical Officer |
Hagit Binder | Chief Operation Officer |
Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer |
Yael Barak | Vice President of Quality and Compliance |
Keren Pushett | Head of Human Resources |
Eidan Loushi | C.R.A. |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 22, 2024 | 6-K | Report of foreign issuer |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 7, 2024 | 6-K | Report of foreign issuer |
Jan 9, 2024 | 6-K | Report of foreign issuer |
Jan 9, 2024 | 6-K | Report of foreign issuer |
Dec 27, 2023 | 424B3 | Prospectus |
Dec 27, 2023 | 6-K | Report of foreign issuer |
Dec 21, 2023 | 6-K | Report of foreign issuer |
Dec 14, 2023 | 424B3 | Prospectus |